LSI Asia 2025 Innovator Spotlight

The inaugural LSI Asia 2025 has set the stage for a groundbreaking year in medtech innovation, with 75 early and growth-stage companies sharing their impressive technologies and milestones. In this special edition, we highlight five standout companies that are driving transformative change in the industry.

Understanding the Medtech Landscape at LSI Asia 2025

LSI Asia 2025 proved to be a catalyst for unveiling the next generation of medical technologies. As global healthcare demands evolve, companies at the forefront of medtech innovation are tackling some of the most pressing challenges across diagnostics, therapeutics, and treatment access.

In this blog, we explore five exciting companies from the summit that have garnered attention for their novel solutions and market potential. These companies are advancing technologies that will shape the future of healthcare and address critical gaps in patient care.

Nanoflex Robotics: Revolutionizing Stroke Treatment

• Presenter: Grace Katzschmann
• Stage: Series A
• Currently Raising: $10,000,000

Nanoflex Robotics is developing remote robotic systems designed to enhance access to life-saving procedures. The company’s advanced magnetic technology and ultra-flexible tools are particularly geared toward treating acute ischemic stroke, enabling remote mechanical thrombectomies.

The global impact of stroke is staggering, with over 6.6 million deaths each year. Yet, a significant portion of ischemic strokes remain untreated due to access challenges. Nanoflex’s innovations aim to bridge this gap by improving access to timely stroke interventions, which can significantly improve patient outcomes.

Riff Medical: Enhancing Aortic Stenosis Treatment

• Presenter: Bo Peng
• Stage: Seed
• Currently Raising: $4,500,000

Riff Medical is advancing intravascular lithotripsy (IVL) therapy to treat severe and symptomatic moderate aortic stenosis (AS). The company’s IVL pretreatment technique may help reduce complications in transcatheter aortic valve replacement (TAVR) procedures, improving prognosis and quality of life for patients with AS.

Severe AS affects an estimated 19.2 million adults aged 75 and above globally. IVL pretreatment could potentially reduce procedural risks, address complications, and ultimately lower the costs of TAVR procedures, which are often burdened by high-risk cases.

Vortex Imaging: Pioneering Accessible Ultrasound Imaging

• Presenter: Tomer Ben-David
• Stage: Series A
• Currently Raising: $12,000,000

Vortex Imaging is developing an innovative ultrasound system that offers operator-independent, 3D volumetric imaging at the point of care. This affordable, cloud-computed technology enables rapid, high-quality imaging for physicians, making it a powerful diagnostic tool in low-resource settings.

The ultrasound market is booming, with a projected 5.9% CAGR through 2029. Vortex’s solution is set to enhance accessibility to diagnostic imaging, particularly in rural and underserved areas, where traditional imaging technologies like CT and MRI are scarce or unaffordable.

Rosalind Dx: Making Non-Invasive Prenatal Testing Accessible

• Presenter: Ella Fung
• Stage: Seed
• Currently Raising: $5,000,000

Rosalind Dx is pioneering non-invasive prenatal testing (NIPT) with its digital PCR-based test (dPCR). By simplifying the testing process, Rosalind is making high-quality NIPT accessible to more labs, offering a solution for detecting congenital abnormalities earlier and at lower costs.

With 3% of live births experiencing congenital abnormalities, the ability to perform accessible, affordable prenatal testing will significantly impact early diagnosis and decision-making. The dPCR market is expected to see rapid growth, reaching a billion-dollar valuation by 2028.

ANEUVO: Non-Invasive Neuromodulation for Chronic Conditions

• Presenter: Yi-Kai Lo
• Stage: Series C
• Currently Raising: $55,000,000

ANEUVO is developing ExaStim, a non-invasive neuromodulation system that has received Breakthrough Device Designation from the FDA for treating paralysis from spinal cord injury. The company is addressing the limitations of invasive devices in the neuromodulation market by focusing on less invasive treatments for chronic conditions.

With a $6 billion neuromodulation devices market, the push for non-invasive solutions is gaining momentum. Companies like ANEUVO are pioneering next-generation technologies aimed at expanding the neuromodulation market to new indications, ultimately improving the quality of life for patients with previously untreatable conditions.

Market Insights: Emerging Medtech Innovation

These companies represent the next wave of medtech innovation, each tackling significant healthcare challenges with creative solutions. Their ability to address unmet needs, improve patient outcomes, and offer cost-effective alternatives is reshaping the future of healthcare. From robotics and diagnostics to non-invasive treatments, these innovators are setting the stage for transformative change in the medtech landscape.

For deeper insights into the innovations that are driving the medtech market, LSI’s Compass platform offers detailed market analysis, competitor data, and forward-looking trends in emerging technologies. Compass helps executives, investors, and medtech professionals stay ahead of the curve in an ever-evolving market.

What's Next?

LSI Asia 2025 highlighted the incredible potential of early and growth-stage companies to disrupt healthcare and improve lives. With groundbreaking technologies across diagnostics, robotics, and therapeutics, the innovators showcased at the event are poised to drive the next generation of medtech advancements.

As these companies continue to evolve, their innovations will undoubtedly reshape the industry and lead to more accessible, efficient, and effective healthcare solutions. The future of medtech is bright, and the momentum from LSI’s events will only continue to accelerate in the years to come.

For a deep dive into these and other presenting companies at LSI Asia ‘25, subscribe to Compass to gain access to 6,600+ proprietary company profiles and deals.